A quantum dot–MUC1 aptamer conjugate for targeted delivery of protoporphyrin IX and specific photokilling of cancer cells through ROS generation

Singh, Seema; Jha, Pravin Kumar; Singh, Vandana; Sinha, K. K.; Hussain, Sahid; Singh, Manoj K.; Das, Prolay

doi:10.1039/c6ib00092d

Cited by 18 publications

(8 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protoporphyrin IX, when conjugated to a ssDNA complementary to the single strand S2.2 aptamer, had no effect on the targeting efficiency of the MUC1 aptamer. The cytotoxicity at 1 pM/μL was 13% greater for the targeted NPs than for the non‐targeted ones …”

Section: The Muc1 Aptamer In Targeted Drug Deliverymentioning

confidence: 95%

Anti‐MUC1 aptamer: A potential opportunity for cancer treatment

Nabavinia

Gholoobi

Charbgoo

et al. 2017

Medicinal Research Reviews

110

View full text Add to dashboard Cite

show abstract

Section: The Muc1 Aptamer In Targeted Drug Deliverymentioning

confidence: 95%

Anti‐MUC1 aptamer: A potential opportunity for cancer treatment

Nabavinia

Gholoobi

Charbgoo

et al. 2017

Medicinal Research Reviews

110

View full text Add to dashboard Cite

show abstract

“…Due to the FRET feature, QDs are able to mediate energy transfer to different photosensitizers and enrich their photodynamic therapeutic effects. In one research conducted by Singh et al, a nanoconjugate was constructed by coupling three modules, including ZnSe/ZnS QDs, MUC1 aptamers, and photosensitizer (protoporphyrin IX, PPIX) [ 165 ] ( Figure 9 b). Upon the specific binding to MUC1 peptides, the FRET between QDs and PPIX mediated QDs to activate PPIX for ROS generation for killing cancer cells.…”

Section: Aptamer-functionalized Non-biological Materials For Therapeutic Applicationsmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

Aptamer-Enabled Nanomaterials for Therapeutics, Drug Targeting and Imaging

Liu

Wang

et al. 2022

Cells

View full text Add to dashboard Cite

A wide variety of nanomaterials have emerged in recent years with advantageous properties for a plethora of therapeutic and diagnostic applications. Such applications include drug delivery, imaging, anti-cancer therapy and radiotherapy. There is a critical need for further components which can facilitate therapeutic targeting, augment their physicochemical properties, or broaden their theranostic applications. Aptamers are single-stranded nucleic acids which have been selected or evolved to bind specifically to molecules, surfaces, or cells. Aptamers can also act as direct biologic therapeutics, or in imaging and diagnostics. There is a rich field of discovery at the interdisciplinary interface between nanomaterials and aptamer science that has significant potential across biomedicine. Herein, we review recent progress in aptamer-enabled materials and discuss pending challenges for their future biomedical application.

show abstract

“…100 Singh et al prepared ZnSe/ZnS QD-PpIX-MUC1 complex capable of simultaneously recognizing MUC1 protein and generating ROS. 101 The PSs protoporphyrin IX (PpIX) were loaded through the hybridization between the complementary ssDNA sequence with the MUC1 strand on ZnSe/ZnS QDs. After that, CF dye was introduced to monitor the combination of MUC1 with MUC1 protein.…”

Section: Aptamer-targeted Photodynamic Therapymentioning

confidence: 99%

Aptamer-Targeted Photodynamic Platforms for Tumor Therapy

Yan

Gao

et al. 2021

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Achieving controlled and accurate delivery of photosensitizers (PSs) into tumor sites is a major challenge in conventional photodynamic therapy (PDT). Aptamer is a short oligonucleotide sequence (DNA or RNA) with a folded three-dimensional structure, which can selectively bind to specific small molecules, proteins, or the whole cells. Aptamers could act as ligands and be modified onto PSs or nanocarriers, enabling specific recognition and binding to tumor cells or their membrane proteins. The resultant aptamer-modified PSs or PSs-containing nanocarriers generate amounts of reactive oxygen species with light irradiation and obtain superior photodynamic therapeutic efficiency in tumors. Herein, we overview the recent progress in the designs and applications of aptamer-targeted photodynamic platforms for tumor therapy. First, we focus on the progress on the rational selection of aptamers and summarize the applications of aptamers which have been applied for targeted tumor diagnosis and therapy. Then, aptamer-targeted photodynamic therapies including various aptamer–PSs, aptamer–nanocarriers containing PSs, and aptamer–nano-photosensitizers are highlighted. The aptamer-targeted synergistically therapeutic platforms including PDT, photothermal therapy, and chemotherapy, as well as the imaging-guided theranostics, are also discussed. Finally, we offer an insight into the development trends and future perspectives of aptamer-targeted photodynamic platforms for tumor therapy.

show abstract

A quantum dot–MUC1 aptamer conjugate for targeted delivery of protoporphyrin IX and specific photokilling of cancer cells through ROS generation

Abstract: A prototype DNA assembled quantum dot-photosensitizer (PS) nanodevice for targeted delivery of PS drug.

Cited by 18 publications

References 45 publications

Anti‐MUC1 aptamer: A potential opportunity for cancer treatment

Anti‐MUC1 aptamer: A potential opportunity for cancer treatment

Aptamer-Enabled Nanomaterials for Therapeutics, Drug Targeting and Imaging

Aptamer-Targeted Photodynamic Platforms for Tumor Therapy

Contact Info

Product

Resources

About